About Vanta Bioscience Limited
Data last updated: 14 July 2026
Vanta Bioscience Limited is a public limited company based in Secunderabad, Telangana, India. It specialises in pharma contract r and d, a part of the broader pharmaceuticals sector. Incorporated on 29 April 2016, the company has been in operation for over 10 years.
Registered with ROC Hyderabad under CIN L74999TG2016PLC109280. Listed on BSE: 540729.
Capital: an authorised share capital of ₹7.5 Cr and a paid-up capital of ₹7.11 Cr. Formerly known as Vanta Bioscience Private Limited. It is led by directors including Dopesh Raja Mulakala and Vyasmurti Madhavrao Shingatgeri.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: No.02/G/308/G No.3/Ff/Sf/1 – 20 – 248 Umajay Complex Rasoolpura, Secunderabad, Telangana, India – 500003.
As per BSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹1.82 Cr, a decline of 7.5% compared to the previous year. The net worth stands at ₹7.11 Cr (down 31.78% YoY). Total assets are valued at ₹66.1 Cr (down 23.03% YoY).
The company has a workforce of approximately 43 employees as per the latest available data. Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Vanta Bioscience. As per MCA filings, the company has open charges of ₹6.57 Cr and satisfied charges of ₹17 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website vantabio.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered AddressNo.02/G/308/G No.3/Ff/Sf/1 – 20 – 248 Umajay Complex Rasoolpura, Secunderabad, Telangana, India – 500003
-
IndustryPharma, Pharma Contract R&D
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Vanta Bioscience Limited
Vanta Bioscience Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74999TG2016PLC109280, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L74999TG2016PLC109280 | Current |
| U74999TG2016PTC109280 | Previous |
| U74999TG2016PLC109280 | Previous |
Associated Brands with Vanta Bioscience Limited
Vanta Bioscience Limited operates one associated brand: Vanta Bioscience. These brands represent Vanta Bioscience Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| GLP-certified preclinical contract research services are provided. | vantabio.com |
Competitors & Alternatives of Vanta Bioscience Limited
Brands and companies operating in the same space as Vanta Bioscience Limited include PHAXIAM, Gubra, BioQual and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
PHAXIAM
|
Antibacterial treatments using bacteriophages are developed for resistant infections. | Lyon, France, France | 2004 |
Gubra
|
Preclinical CRO services for NAFLD/NASH, diabetes, and obesity are provided. | Horsholm, Denmark, Denmark | 2008 |
BioQual
|
Contract research on infectious disease models is conducted. | Rockville, United States, United States | 1981 |
Tigermed
|
Drug development and preclinical services are provided by Tigermed. | Hangzhou, China, China | 2004 |
Gentronix
|
In-vitro and in-vivo genetic toxicology screening services are provided. | Alderley Edge, United Kingdom, United Kingdom | 1999 |
Aquila BioMedical
|
Preclinical services in immunology, regeneration, neuroscience, and histology are provided. | Edinburgh, United Kingdom, United Kingdom | 2011 |
ReveraGen
|
Steroids for Duchenne muscular dystrophy treatment are developed. | Rockville, United States, United States | 2008 |
VGXI
|
Contract developer and manufacturer of plasmids | The Woodlands, United States, United States | 1997 |
Shanghai Semero Biotechnology
|
Diversified preclinical services for brain-related disorders are provided. | Shanghai, China, China | 2014 |
Business Activity of Vanta Bioscience Limited
Vanta Bioscience Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including architecture, engineering activities, technical testing and analysis activities.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M4 | Architecture, engineering activities, technical testing and analysis activities | Locked |
Business activity turnover details for Vanta Bioscience Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Vanta Bioscience Limited
Vanta Bioscience Limited is audited by Mathesh & Ramana (ICAI peer reviewed, certificate valid till 2026-07-20) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Mathesh & Ramana (ICAI peer reviewed, certificate valid till 2026-07-20) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Vanta Bioscience Limited
Vanta Bioscience Limited is currently managed by 5 directors, with 7 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Dopesh Raja Mulakala | Managing Director | 29 Apr 2016 | 10 Years 3 Months | Current |
|
Vyasmurti Madhavrao Shingatgeri
Also directs:
Vanta Bioscience Limited, Spectrogen Pharmachem Limited
|
Whole-Time Director | 08 Feb 2017 | 9 Years 6 Months | Current |
|
Padmanabhuni Venkata Appaji
Also directs:
Vanta Bioscience Limited, Vasudha Pharma Chem Limited, Genphex Life Sciences Private Limited and 1 more
|
Director | 20 Mar 2017 | 9 Years 4 Months | Current |
|
Gonuguntla Kathyayani
Also directs:
Vanta Bioscience Limited, Vasudha Pharma Chem Limited
|
Director | 19 May 2017 | 9 Years 2 Months | Current |
| Yogeswara Rao Danda | Director | 22 May 2019 | 7 Years 2 Months | Current |
Financials of Vanta Bioscience Limited FY 2026 filings available
Vanta Bioscience Limited reported revenue of ₹1.82 Cr (down 7.5% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1.82 Cr | ₹1.96 Cr | ₹9.72 Cr | ₹6.28 Cr | ₹9.69 Cr | ₹10.04 Cr | ₹14.14 Cr | ₹12.48 Cr |
| Other Income | ₹15.95 Lakh | ₹11.07 Lakh | ₹10.64 Lakh | ₹68.72 Lakh | ₹42.31 Lakh | ₹3.45 Lakh | ₹10.99 Lakh | ₹22.96 Lakh |
| Total Income | ₹1.98 Cr | ₹2.07 Cr | - | - | - | - | - | - |
| Cost of Materials Consumed | ₹14.13 Lakh | ₹34.55 Lakh | ₹1.1 Cr | ₹83.34 Lakh | ₹70.21 Lakh | ₹81.89 Lakh | ₹1.18 Cr | ₹1.4 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹1.03 Cr | ₹98.95 Lakh | -₹38.18 Lakh | ₹11.42 Lakh | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹61.15 Lakh | ₹2.06 Cr | ₹3.79 Cr | ₹3.94 Cr | ₹3.09 Cr | ₹2.83 Cr | ₹5.07 Cr | ₹4.15 Cr |
| Finance Costs | ₹77.73 Lakh | ₹4.07 Cr | ₹5.75 Cr | ₹5.89 Cr | ₹2.35 Cr | ₹2.14 Cr | ₹1.95 Cr | ₹1.69 Cr |
| Other Expenses | ₹1.08 Cr | ₹2.82 Cr | ₹3.9 Cr | ₹3.78 Cr | ₹2.43 Cr | ₹2.45 Cr | ₹3.52 Cr | ₹3.66 Cr |
| Total Expenses | ₹1.96 Cr | ₹14.7 Cr | ₹18.66 Cr | ₹17.23 Cr | ₹9.88 Cr | ₹9.48 Cr | ₹12.91 Cr | ₹11.61 Cr |
| Profit Before Tax | ₹1.37 Lakh | -₹12.63 Cr | -₹8.83 Cr | -₹10.26 Cr | ₹22.84 Lakh | ₹58.92 Lakh | ₹1.34 Cr | ₹1.1 Cr |
| Total Tax Expense | -₹9.46 Lakh | ₹66.1 Lakh | -₹22.02 Lakh | ₹18.19 Lakh | ₹14.02 Lakh | ₹14.09 Lakh | ₹32.91 Lakh | ₹40.47 Lakh |
| Net Profit | ₹10.83 Lakh | -₹4.77 Cr | -₹2.32 Cr | -₹6.48 Cr | ₹8.82 Lakh | ₹44.96 Lakh | ₹1 Cr | ₹69.66 Lakh |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹66.1 Cr | ₹85.88 Cr | ₹85.4 Cr | ₹84.71 Cr | ₹81.4 Cr | ₹69.63 Cr | ₹48.57 Cr | ₹38.56 Cr |
| Non-current Assets | ₹51.97 Cr | ₹70.52 Cr | ₹68.24 Cr | ₹69.47 Cr | ₹66.91 Cr | ₹49.69 Cr | ₹28.73 Cr | ₹22.93 Cr |
| Current Assets | ₹14.13 Cr | ₹15.36 Cr | ₹17.16 Cr | ₹15.24 Cr | ₹14.5 Cr | ₹19.94 Cr | ₹19.85 Cr | ₹15.63 Cr |
| Property, Plant & Equipment | ₹9.68 Cr | ₹23.96 Cr | - | - | - | - | - | - |
| Inventories | ₹7.53 Cr | ₹6.51 Cr | ₹7.52 Cr | ₹7.16 Cr | ₹7.24 Cr | ₹9.76 Cr | ₹14.01 Cr | ₹9.24 Cr |
| Cash & Equivalents | ₹13.54 Lakh | ₹0 | ₹0 | ₹9.66 Lakh | ₹22.42 Lakh | ₹2.65 Cr | ₹6.41 Lakh | ₹1.81 Cr |
| Equity (Net Worth) | ₹7.11 Cr | ₹10.42 Cr | - | - | - | - | - | - |
| Current Liabilities | ₹11.82 Cr | ₹26.56 Cr | ₹22.88 Cr | ₹17.75 Cr | ₹17.76 Cr | ₹14.84 Cr | ₹9.87 Cr | ₹3.21 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹5.22 Cr | -₹2.41 Cr | ₹2.68 Cr | -₹62.76 Lakh | ₹5.28 Cr |
| Investing Cash Flow | -₹6.87 Cr | -₹6.69 Cr | -₹3.31 Cr | -₹5.91 Cr | -₹17.18 Cr |
| Financing Cash Flow | ₹12.08 Cr | ₹9.16 Cr | ₹69.32 Lakh | ₹6.41 Cr | ₹9.48 Cr |
| Capital Expenditure | ₹93,000 | ₹6.69 Cr | - | - | - |
| Free Cash Flow (computed) | -₹5.23 Cr | -₹9.1 Cr | - | - | - |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹1.22 Lakh | ₹6.1 Lakh | ₹6.4 Lakh | -₹12.76 Lakh | -₹2.43 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1.82 Cr | ₹1.13 Cr | ₹8.56 Cr | ₹5.17 Cr | ₹9.35 Cr | ₹10.04 Cr | ₹14.11 Cr | ₹12.42 Cr |
| Other Income | ₹15.95 Lakh | ₹3.92 Lakh | ₹4.77 Lakh | ₹62.53 Lakh | ₹16.77 Lakh | ₹2.15 Lakh | ₹10.88 Lakh | ₹22.88 Lakh |
| Total Income | ₹1.98 Cr | ₹1.17 Cr | - | - | - | - | - | - |
| Cost of Materials Consumed | ₹14.12 Lakh | ₹7.35 Lakh | ₹64.75 Lakh | ₹56.84 Lakh | ₹62.32 Lakh | ₹81.89 Lakh | ₹1.18 Cr | ₹1.4 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹1.03 Cr | ₹98.95 Lakh | -₹38.18 Lakh | ₹11.42 Lakh | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹61.15 Lakh | ₹58.29 Lakh | ₹2.68 Cr | ₹2.79 Cr | ₹2.99 Cr | ₹2.83 Cr | ₹4.94 Cr | ₹4.15 Cr |
| Finance Costs | ₹77.73 Lakh | ₹66.26 Lakh | ₹2.42 Cr | ₹3.11 Cr | ₹2.11 Cr | ₹2.06 Cr | ₹1.95 Cr | ₹1.69 Cr |
| Other Expenses | ₹1.07 Cr | ₹1.14 Cr | ₹1.96 Cr | ₹2.18 Cr | ₹2.33 Cr | ₹2.5 Cr | ₹3.68 Cr | ₹3.6 Cr |
| Total Expenses | ₹1.95 Cr | ₹3.89 Cr | ₹8.56 Cr | ₹10 Cr | ₹9.38 Cr | ₹9.45 Cr | ₹12.93 Cr | ₹11.56 Cr |
| Profit Before Tax | ₹2.53 Lakh | -₹2.72 Cr | ₹4.17 Lakh | -₹4.21 Cr | ₹13.96 Lakh | ₹60.5 Lakh | ₹1.29 Cr | ₹1.1 Cr |
| Total Tax Expense | -₹9.45 Lakh | ₹5.96 Lakh | -₹94,000 | ₹2.81 Lakh | ₹6.11 Lakh | ₹13.47 Lakh | ₹31 Lakh | ₹40.38 Lakh |
| Net Profit | ₹11.98 Lakh | -₹2.78 Cr | ₹5.11 Lakh | -₹4.24 Cr | ₹7.85 Lakh | ₹47.03 Lakh | ₹97.8 Lakh | ₹69.38 Lakh |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹66.11 Cr | ₹55.84 Cr | ₹52.91 Cr | ₹51.64 Cr | ₹50.4 Cr | ₹46.25 Cr | ₹41.59 Cr | ₹38 Cr |
| Non-current Assets | ₹51.09 Cr | ₹45.44 Cr | ₹40.88 Cr | ₹40.51 Cr | ₹39.4 Cr | ₹32.74 Cr | ₹24.11 Cr | ₹23.95 Cr |
| Current Assets | ₹15.03 Cr | ₹10.39 Cr | ₹12.03 Cr | ₹11.13 Cr | ₹11 Cr | ₹13.51 Cr | ₹17.48 Cr | ₹14.05 Cr |
| Property, Plant & Equipment | ₹9.68 Cr | ₹10.9 Cr | - | - | - | - | - | - |
| Inventories | ₹7.53 Cr | ₹6.48 Cr | ₹7.48 Cr | ₹7.16 Cr | ₹7.24 Cr | ₹9.76 Cr | ₹14.01 Cr | ₹9.24 Cr |
| Cash & Equivalents | ₹12.93 Lakh | ₹0 | ₹14.14 Lakh | ₹6.65 Lakh | ₹6.91 Lakh | ₹6.67 Lakh | ₹6.41 Lakh | ₹28.42 Lakh |
| Equity (Net Worth) | ₹7.11 Cr | ₹17.13 Cr | - | - | - | - | - | - |
| Current Liabilities | ₹11.76 Cr | ₹18.57 Cr | ₹14.2 Cr | ₹10.25 Cr | ₹13.46 Cr | ₹10.85 Cr | ₹7.13 Cr | ₹3.19 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹5.22 Cr | ₹57.18 Lakh | ₹4.55 Cr | ₹64.47 Lakh | ₹6.35 Cr |
| Investing Cash Flow | -₹6.87 Cr | -₹5 Cr | -₹1.67 Cr | -₹2.53 Cr | -₹8.05 Cr |
| Financing Cash Flow | ₹12.08 Cr | ₹4.43 Cr | -₹2.81 Cr | ₹1.88 Cr | ₹1.71 Cr |
| Capital Expenditure | ₹93,000 | -₹78.96 Lakh | - | - | - |
| Free Cash Flow (computed) | -₹5.23 Cr | -₹21.78 Lakh | - | - | - |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹1.21 Lakh | ₹0 | ₹7.48 Lakh | -₹26,000 | ₹24,000 |
Shareholding Pattern of Vanta Bioscience Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 72.81%, retail and other public shareholders hold 27.19% of Vanta Bioscience Limited. The company had 426 shareholders on record.
| Mar 2026 | Sep 2025 | Mar 2025 | Sep 2024 | Mar 2024 | Sep 2023 | |
|---|---|---|---|---|---|---|
| Promoters | 72.81% | 72.81% | 69.36% | 69.36% | 69.36% | 69.36% |
| Public | 27.19% | 27.19% | 30.64% | 30.64% | 30.64% | 30.64% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|---|
| Promoters | 72.81% | 69.36% | 69.36% | 69.36% | 69.00% | 69.11% |
| Public | 27.19% | 30.64% | 30.64% | 30.64% | 31.00% | 30.89% |
| Promoter change (YoY, %pts) | +3.45 | +0.00 | +0.00 | +0.36 | -0.11 | - |
Group Structure of Vanta Bioscience Limited
Vanta Bioscience Limited has 1 subsidiary company and 1 associated company. This group structure data is as of FY 2023. The corporate group structure reflects Vanta Bioscience Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Vanta Clinical Research Limited | U73100TG2018PLC126673 | - |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Vanta Bioscience Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Mar 2017 | State Bank of India | ₹6.57 Cr | Open |
| 03 Dec 2019 | Axis Bank Limited | ₹17 Cr | Satisfied |
Total charge records: 2 View all charges
Employees and EPFO Compliance at Vanta Bioscience Limited
Vanta Bioscience Limited has a workforce of 43 employees as of Mar 22, 2024.
Employee and EPFO history for Vanta Bioscience Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Vanta Bioscience Limited
GST registrations and filing compliance for Vanta Bioscience Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Vanta Bioscience Limited
Credit ratings, litigation, and regulatory alerts for Vanta Bioscience Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Vanta Bioscience Limited
MSME payment history for Vanta Bioscience Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Vanta Bioscience Limited
Corporate group structure for Vanta Bioscience Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Vanta Bioscience Limited
MCA filings and documents for Vanta Bioscience Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Vanta Bioscience Limited
Frequently Asked Questions about Vanta Bioscience Limited
Vanta Bioscience Limited is an active public limited company in the pharma sector based in Secunderabad, Telangana, India. It was incorporated on 29 April 2016 (10+ years old) and is registered under CIN L74999TG2016PLC109280. Listed on BSE: 540729. The company has 43 employees.
Vanta Bioscience Limited reported revenue of ₹1.82 Cr for FY 2026 (down 7.5% YoY) based on consolidated BSE filings.
The current directors of Vanta Bioscience Limited are:
- Dopesh Raja Mulakala - Managing Director
- Vyasmurti Madhavrao Shingatgeri - Whole-Time Director
- Padmanabhuni Venkata Appaji - Director
- Gonuguntla Kathyayani - Director
- Yogeswara Rao Danda - Director
The primary industry of Vanta Bioscience Limited is pharma. The company specifically operates in pharma contract r and d. The company is currently active in this sector.
Yes. Vanta Bioscience Limited is listed on BSE with code 540729.
Vanta Bioscience Limited can be reached at the registered office: No.02G308G No.3FfSf1 – 20 – 248 Umajay Complex Rasoolpura, Secunderabad, Telangana, India – 500003, or through the website vantabio.com.